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As with the development of any novel and potentially
powerful technology, the prospect of revealing new in-
formation that may dramatically change our under-
standing of biological processes can generate much
excitement. Such is true for the emerging genomic ap-
proaches that make possible high-density assays using
microarray platforms. Indeed, it is di⁄cult, if not im-
possible, to imagine any area of biology that could not
be a¡ected by the wide range of potential applications
of microarray technology. Numerous examples, such as
those from the ¢eld of oncology, provide striking evi-
dence of the power of microarrays to bring about extra-
ordinary advances in molecularly de¢ning important
disease phenotypes that were otherwise unrecognized
using conventional approaches such as histology. How-
ever, only a few studies in autoimmunity are available
to date. Very recent work in alopecia areata, multiple
sclerosis, systemic lupus erythematosus, and Sj˛gren’s
syndrome illustrates the potential for gaining new in-
sights into the pathophysiology of these complex autoim-
mune disorders on a global, molecular scale. These new
insights are likely to signi¢cantly improve our under-
standing of disease processes, diagnosis, identi¢cation of
new therapeutic targets, and identi¢cation of patients
most likely to bene¢t from speci¢c and tailored thera-
pies. Key words: microarrays, autoimmunity, autoimmune




icroarray technology provides an unprecedented
and uniquely comprehensive probe into the co-
ordinated workings of entire biological path-
ways and genomic-level processes. In general
terms, microarrays refer to a variety of platforms
in which high-density assays are performed in parallel on a solid
support. Thousands to tens of thousands of datapoints may be
generated in each experiment. The growth of scienti¢c literature
since the mid-1990s may provide some indication of the potential
impact of this technology in the biomedical sciences (Fig 1). Of
the approximately 1900 articles published through 2002 with
reference to microarrays, however, less than two dozen include
applications directly investigating autoimmune disease pheno-
types. A majority of applications have been in oncology, although
many examples from other ¢elds are rapidly emerging and in-
clude examination of host response to pathogens, examination
of drug responses, identi¢cation of temporal changes in gene ex-
pression, and comparisons of various experimental conditions.
Three major types of microarrays existtissue, protein, and
DNA. Tissue microarrays immobilize small amounts of tissue
from biopsies of multiple subjects on glass slides for immunohis-
tochemical processing; protein arrays immobilize peptides or in-
tact proteins for detection by antibodies or other means (see
below). For the last several years, much excitement and attention
has focused on DNA microarrays. Regardless of the speci¢c plat-
form used, these approaches o¡er new opportunities to address
biologic questions in a way never before possible. Table 1 pro-
vides just a few examples of the potential ways in which micro-
array technology can be utilized.
We provide here a general discussion of the most common mi-
croarray technologies and highlight some selected examples of
how this approach is being applied to gain insight into immuno-
logic and autoimmune disease processes. For those just entering
the microarray arena or interested in more details, a series of par-
ticularly useful reviews have recently been published that take
stock of the latest developments and discuss the most pressing
challenges of this technology (Trent and Baxevanis, 2002).
Autoantigen and cytokine microarrays Applications of pro-
tein microarrays include assessment of enzyme^substrate,
protein^protein, and DNA^protein interactions. Although
e¡orts to develop these proteomic tools predate the ¢rst
descriptions of DNA microarrays (MacBeath, 2002), progress
has been relatively slower, in part because of challenges posed by
natural inherent di¡erences in proteins compared with DNA. As
examples, proteins consist of highly diverse conformational
structures that result from 20 amino acids versus the 4 nucleic
acid building blocks that generate a relatively uniform structure
in DNA. Proteins may exist as large complexes; they may be
hydrophilic or hydrophobic, acidic or basic; and they may
contain post-translational modi¢cations such as acetylation,
glycosylation, or phosphorylation. Functional and conformation
properties of proteins must often remain intact when
immobilized onto a microarray in order to retain the desired
binding properties for detection of target ligands.
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The development of protein microarrays to detect immuno-
logic targets such as cytokines or autoantibodies has enormous
potential for research and diagnostic applications in autoimmune
diseases. Several groups, including Joos and colleagues in
Germany (Joos et al, 2000) and Robinson and colleagues at
Stanford University (Robinson et al, 2002), have made important
strides in developing autoantigen microarrays for multiplex
characterization of autoimmune serum. Joos and colleagues
spotted 18 common autoantigens onto silane-treated glass slides
and nitrocellulose at serial dilutions. Bound antibodies from
minimal amounts of 25 characterized autoimmune serum
samples and 10 normal blood donors were titered by using
variable amounts of autoantigen. The autoimmune serum
samples were obtained from patients with autoimmune
thyroiditis (Hashimoto’s thyroiditis and Graves’ disease), systemic
lupus erythematosus (SLE), Sj˛gren’s Syndrome (SS), mixed
connective tissue disease (MCTD), scleroderma, polymyositis,
systemic vasculitis, and antiphospholipid syndrome. These assays
proved to be highly speci¢c and similar in sensitivity when
compared to a standard ELISA format. Further developments
will include optimizing the nature of the autoantigen material
to minimize possible loss of antigenicity and expanding the
representation of autoantigens on the array.
Robinson and colleagues developed a 1152-feature array
containing 196 distinct biomolecules that represent major auto-
antigens targeted by antibodies produced by rheumatic autoimmune
disease patients (Robinson et al, 2002). The autoantigens include
hundreds of proteins, peptides, DNA, enzymatic complexes, and
ribonucleoprotein complexes. Examples of autoantigens spotted
include Ro52, Ro60, La, jo-1, Sm-B/B0, U1-70 kDa, U1
snRNP-C, topoisomerase 1, pyruvate dehydrogenase (PDH), and
histone H2A. The arrays were characterized using multiple sera
from eight human autoimmune diseases and included SLE, SS,
MCTD, polymyositis, primary biliary cirrhosis, rheumatoid
arthritis (RA), and both limited and di¡use forms of
scleroderma. This work demonstrates the feasibility of using
large-scale, £uorescence-based autoantigen microarrays to detect
human autoantibodies with simple protocols and widely
available equipment in a low-cost and low-sample volume
format. Some of the potential applications for this technology
include (1) rapid screening for autoantibody speci¢cities to
facilitate diagnosis and treatment; (2) characterization of the
speci¢city, diversity, and epitope spreading of autoantibody
responses; (3) determination of the isotype subclass of speci¢c
autoantibodies; (4) guiding the development and selection of
antigen-speci¢c therapies; and (5) use as a discovery tool to
identify novel autoantigens or epitopes.
Microarrays that simultaneously detect multiple cytokines have
been developed by Huang and colleagues at Emory University
(Huang et al, 2001). Their method utilizes captured antibodies
spotted onto membranes, incubation with biological samples
such as patient serum, and detection by biotin-conjugated
antibodies and enzymatic-coupled enhanced chemiluminescence.
Twenty-eight cytokines have been detected using this method,
including interleukins-1a, 2, 3, 5, 6, 7, 8, 10, 13, and 15; tumor
necrosis factors a, b, and b1; interferon-g, and others. In
addition to detecting multiple cytokines simultaneously, these
assays were shown to be more sensitive than conventional
ELISAs, with broader detection ranges. The ability to readily
scale up this approach to include much larger numbers of
cytokines and other proteins will undoubtedly fuel further
development of this powerful tool for studying complex and
dynamic cellular processes such as immune reactions, apoptosis,
cell proliferation, and di¡erentiation.
DNA and oligonucleotide microarrays DNA microarrays
were ¢rst introduced in the mid-1990s (Schena et al, 1995) and
have been the most widely utilized application of microarray
technology. There are two commonly available DNA microarray
types. First are the cDNA microarrays fabricated by robotic
spotting onto glass slides of PCR products derived primarily
from the 30 end of genes and expressed sequence tags (EST).
This is the method popularized by, among others, Patrick
Brown at Stanford and Louis Staudt at the NIH (DeRisi et al,
1997; Alizadeh et al, 1998). The second type uses in situ synthes-
ized oligonucleotide arrays fabricated using photolithographic
chemistry on silicon chips. This is the method used in the
proprietary A¡ymetrix system (Pease et al, 1994). The data
generated using these two systems are highly concordant, as
demonstrated in parallel studies of the yeast cell cycle (Cho et al,
1998; Spellman et al, 1998). In the spotted cDNA microarray
system, two probes with di¡erent £uorescent tags are hybridized
to the same array, one serving as the experimental condition and
the other as a control. The ratio of hybridization between the two
probes is calculated, allowing a quantitation of the hybridization
signal for each spot on the array. In this system, the probe is ¢rst-
strand cDNA generated by oligo-dT primed reverse transcription
from an RNA sample (for additional details see http://
cmgm.stanford.edu/pbrown/). In the A¡ymetrixTM system, only
a single labeled probe is used and each gene on the chip is
represented by 8 to 10 wild-type 25-mer oligonucletides and the
same number of single-base mutant 25-mer oligonucleotides
synthesized next to one another on the array. Signal intensity
and the ratio of speci¢c to nonspeci¢c hybridization allows
the generation of quantitative data regarding gene expression in
the sample (for more details see http://www.a¡ymetrix.com/
technology/tech_probe.html).
Data analysis Microarray analysis is often considered discovery
based rather than hypothesis driven (Albelda and Sheppard, 2000;
Staudt and Brown, 2000), largely because of the potential for
discovering altered expression of novel genes for which little or
no prior information is available to suggest a role in the disease or
experimental condition examined. High-quality experiments,
however, are driven by addressing a scienti¢c question (even if it
Table1. Potential objectives of studies utilizing microarray
technology
1. Distinguish patients from normal controls
2. Identify subsets of patients
3. Characterize host responses
4. Examine cellular pathways
5. Compare alternative experimental conditions
6. Examine drug response
7. Follow temporal changes in gene expression
8. Identify candidate genes for genetic studies
Figure1. Growth in number of microarray publications. Resulting
number of articles retrieved using PubMed searches with the term ‘‘micro-
array’’and limited to English are shown for each year.
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is simply ‘‘Are there genes that are di¡erentially expressed
between a group of patients and controls?’’), consistency in
execution of experimental protocols, use of sample sizes with as
many replicates as is feasible, and a plan for statistical analysis and
interpretation of the data. Including statistical expertise during
the early phase of experimental design (i.e., prior to any data
collection) is critical, particularly in the setting of microarray
analysis, where each experiment can carry signi¢cant cost.
There are generally three approaches to data analysis:
prognostic prediction, class discovery, and class comparison
(Simon et al, 2002). Prognostic prediction methods are used
when two or more groups of samples are analyzed and the goal
is to develop a model for prediction of class membership for new,
additional samples. This approach is common in studies designed
to predict various clinical outcomes, such as treatment
e¡ectiveness or duration of survival in patients with cancer. Class
discovery is often applied to datasets with a heterogeneous
sample and the objective is to identify novel subsets of samples
that may not otherwise be discernable using conventional
techniques such as histological or morphological criteria. Class
comparison involves two or more prede¢ned groups, such as
patients and controls, for which a function is determined that
¢nds the genes that best discriminate between the groups. For
each of these approaches, numerous statistical methods exist, and
there is no ‘‘one size ¢ts all’’ for the analysis and interpretation of
the complex datasets generated by microarray studies (Slonim,
2002). Data analysis and interpretation are very active areas of
research that require synergistic e¡orts from biologists,
computer scientists, and statisticians in order to maximize the
full potential of these powerful microarray technologies
(Slonim, 2002).
APPLICATIONS OF MICROARRAYS IN AUTOIMMUNE
DISEASES ^ LESSONS FROM CANCER
Over the last few years, there has been an understandably high
level of excitement concerning the power of microarrays to radi-
cally change the level at which we understand biological systems
(Staudt and Brown, 2000). This excitement has been bolstered by
many successful applications in which important new insights
have been gained, particularly in oncology. Microarrays have
been used to identify new candidate genes for prostate cancer
(Walker et al, 1999), to identify ‘‘sets’’ of genes that function in
pathways such as cell proliferation or di¡erentiation (Geiss et al,
2000; Ichikawa et al, 2000), and to distinguish previously unrec-
ognized subtypes of clinical disease (St. Croix et al, 2000, Aliza-
deh et al, 2000). For example, underlying molecular heterogeneity
in lymphoid malignancies has been revealed by Staudt and col-
leagues at NIH (Alizadeh et al, 1998; Eisen et al, 1998; Alizadeh
et al, 2000). Gene expression pro¢les were identi¢ed that revealed
two molecularly distinct forms of di¡use large B cell lymphoma
(DLBCL) representative of di¡erent stages of B cell development.
These tumors were clinically indistinguishable prior to microar-
ray analyses. Importantly, the subset of patients bearing tumors
with the germinal center B-like signature had a better overall sur-
vival than patients with the activated B-like DLBCL pro¢le.
Other examples of improved or previously impossible classi¢-
cation of groups of heterogeneous tumors based on distinct gene
expression pro¢les have been described for central nervous sys-
tem embryonal tumors (Pomeroy et al, 2002), primary breast can-
cer (Bertucci et al, 2000), and cutaneous malignant melanoma
(Bittner et al, 2000). In addition, analysis of gene expression pat-
terns for 60 cancer cell lines available through the National Can-
cer Institute demonstrated consistent relationships between the
pro¢les observed and the tissue of origin (Schuler, 1997), further
supporting the utility of this approach for classi¢cation of disease
at the molecular level. These studies provide convincing evidence
that microarrays can be used to identify previously undetected
but clinically relevant gene expression signatures in human disease.
Gene expression pro¢ling in autoimmune diseases
Autoimmune diseases a¡ect 3%^5% of the population and are
mediated by an immune response to self antigens that may
range from relatively organ or tissue speci¢c to systemic in
nature. Several lines of evidence support the suggestion that
certain genes that contribute to autoimmunity may be shared by
multiple disease phenotypes. Multiple autoimmune diseases are
often found in families or individuals; they share overlapping
susceptibility loci, as demonstrated by genome wide scans; and
apparently healthy relatives of autoimmune disease patients often
exhibit immune system abnormalities. What predisposes some
individuals to develop an autoimmune disease and the factors
that impart speci¢city of the disease phenotype are not clear.
Relatively few studies of gene expression pro¢ling in auto-
immune disease have been published to date; however, this will
undoubtedly improve in the near future as e¡orts in our
laboratories and others’ progress. As with examples from other
¢elds, the diversity of experimental designs in autoimmune
disease studies published to date o¡ers hints of the powerful
nature of microarray approaches. A few speci¢c examples of
results from several autoimmune diseases follow.
Alopecia areata (AA) is considered to be a nonscarring,
in£ammatory, cell-mediated autoimmune disease characterized
by spontaneous reversible hair loss that most frequently a¡ects
the scalp. In studies by Carroll and colleagues, gene expression
pro¢les were examined in a mouse model of AA and in humans
with AA (Carroll et al, 2002). Total RNA was extracted at
multiple time points from skin of the C3H/HeJ inbred mouse
strain with AA induced by AA-a¡ected skin grafts, as well as
from C3H/HeJ mice with spontaneous, chronic, extensive AA.
The kinetic progression of gene expression in the induced
model of AAwas consistent with an autoimmune mechanism of
disease progression. The earliest markers suggested that onset of
disease involves tissue in£ammation and vasodilation,
proceeding to activation of macrophages and T helper 1 (TH1)
lymphocytes, followed by alterations in expression levels of
genes regulating immunoglobulin responses during later disease
development. Downregulation of hair keratins and hair follicle^
associated genes was coincident with activation of macrophages
and T cells, and suggested that disintegration or collapse of hair
follicle integrity is initiated by immune system attack, rather
than by an immune response being invoked by hair follicle
damage. Genes that were upregulated in studies of human skin
biopsies from individuals with chronic, nonresponsive AA were
suggestive of changes associated with chronic, innate immunity
and in¢ltration of TH1 T cells. Genes involved in a variety of
metabolic, adhesion, and signaling processes that previously had
not been associated with AA were also upregulated. Of the 64
genes that were de¢ned as downregulated, 15 are associated with
human keratins or hair follicles. These results demonstrate the
importance of cell-mediated immunological disease in AA and
provide an important example of how new insights into the
pathogenesis of autoimmune disease may be obtained through
microarray technology.
An important and common goal for autoimmune disease
research is the identi¢cation of new targets for the development
of more speci¢c and e¡ective therapies. A powerful illustration of
the potential value of microarray technology in making progress
toward this goal was recently reported in studies of multiple
sclerosis (MS) (Lock et al, 2002; Tompkins and Miller, 2002). MS
is a chronic autoimmune disease involving demyelination of the
central nervous system (CNS) white matter. Lock and colleagues
described gene expression pro¢les for two distinct types of brain
lesions in autopsy material obtained from MS patients: acute/
active lesions characterized by in£ammation and chronic/silent
lesions with extensive scarring and demyelination (Lock et al,
2002). The authors described numerous genes that are di¡-
erentially expressed between MS lesions and normal tissue, as
well as genes that di¡erentiate the acute and chronic lesions.
From the genes identi¢ed, two were then chosen as potential
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therapeutic targets and tested in a common murine model of MS,
experimental autoimmune encephalomyelitis (EAE). The
immunoglobulin Fc receptor I and IgE receptor genes were
upregulated in chronic/silent lesions. Comparison of the severity
of disease in Fc receptor-de¢cient and wild-type mice showed
that acute disease was less severe and chronic disease was absent
in mice lacking Fc receptor expression. The second gene targeted
as a potential target was granulocyte-colony stimulating factor
(G-CSF), which was elevated in the acute/active patients. Treat-
ment with G-CSF was shown to decrease disease severity in the
early stages of EAE when given before disease onset. Studies such
as these provide important insight into distinct stages of disease
and may facilitate development of tailored therapies for di¡erent
forms of MS.
Genome scans have been the workhorse in linkage studies
aimed at identi¢cation of susceptibility loci in complex auto-
immune diseases such as systemic lupus erythematosus (SLE).
SLE is often touted as the prototype systemic autoimmune
disease. Gene-mapping studies in both mice and humans
have identi¢ed numerous genomic regions that are currently
under intense scrutiny in e¡orts to identify speci¢c SLE genes
(Ga¡ney et al, 2002; Nguyen et al, 2002). Once linkage is
identi¢ed, the chromosomal region may be found to contain
several hundred candidate genes for further evaluation.
Microarrays provide an important complementary tool for
identifying genes within linked regions that may display altered
expression, perhaps as a result of polymorphisms that a¡ect
mRNA transcription. In the (NZBNZW)F1 mouse model of
lupus, Nba2 is a major contributor to disease susceptibility and is
thought to represent a quantitative trait locus important in
production of IgG antibodies to nearly all of the lupus
autoantibodies commonly studied (Rozzo et al, 2001). By using
oligonucleotide arrays, Rozzo and colleagues identi¢ed two
genes with di¡erential expression that localized to the Nba2
interval (Rozzo et al, 2001). Through additional studies, these
authors provide convincing evidence that the interferon-
inducible gene, i¢202, represents a strong candidate gene for
SLE. This work thus exempli¢es the potential power of
microarray analysis to greatly facilitate identi¢cation of a
susceptibility gene in a linked region.
Microarray studies in human SLE have recently identi¢ed gene
expression pro¢les that distinguish most patients from controls
(Baechler et al, 2003). Baechler and colleagues examined 48
patients and 42 healthy controls using oligonucleotide array
analysis of peripheral blood mononuclear cells. Interestingly, the
arrays identi¢ed a subset of patients that show dysregulated
expression of genes in the interferon (IFN) pathway. This IFN
signature was associated with a more severe form of the disease,
particularly involving complications related to kidney and/or
central nervous system in£ammation. Therapeutic targeting of
the IFN pathway may thus be particularly bene¢cial in the
subset of SLE patients with severe disease that demonstrate the
IFN signature.
The underlying mechanisms that contribute to autoimmune
disease may in part be shared among related phenotypes. This is
thought to be likely for Sj˛gren’s syndrome (SS) and related
diseases such as SLE or RA. SS is a chronic autoimmune disease
that may occur as the primary phenotype or as a secondary
syndrome when present in the context of an additional
autoimmune disease. It is characterized by focal lymphocytic
in¢ltration of lacrimal and salivary glands, leading to dry eyes
and dry mouth, and is frequently accompanied by a variety of
extraglandular manifestations. Immunological features of disease
that overlap among SS, SLE, and RA include production of anti-
Ro/SSA and/or anti-La/SSB autoantibodies produced by many
patients with either SLE or SS, and the production of
rheumatoid factor antibodies, which are often found in RA or
SS patients. Ongoing microarray studies of SS in our laboratory
using methods very similar to those described for SLE by
Baechler and colleagues have shown that genes inducible by
interferons are upregulated in SS patients compared with
healthy controls (Moser KL, unpublished observations). Both
SLE and SS may thus share a common etiologic mechanism
mediated through dysregulation of genes involved in the IFN
pathway. Further application of microarray analyses should
facilitate identi¢cation of both pathways that are common to
SLE and SS, as well as pathways that uniquely distinguish
patients with these disease phenotypes.
Studies comparing gene expression pro¢les among patients
with SLE, RA, Type I diabetes, and MS also suggest that
aberrant gene expression pro¢les may be similar among
clinically distinct autoimmune disease phenotypes (Maas et al,
2002). Using cDNA microarrays with 44000 genes, Maas and
colleagues ¢rst measured gene expression in nine healthy control
subjects before and after immunization with in£uenza vaccine,
and de¢ned pro¢les associated with normal immune responses.
Comparisons of normal immune response pro¢les and
autoimmune disease pro¢les indicated that patterns in gene
expression among RA and SLE patients and in MS and Type 1
diabetes patients are relatively similar. Genes that are
overexpressed in all four autoimmune diseases represented various
receptors, in£ammatory mediators, signaling/secor messenger
molecules, and autoantigens. Many of the downregulated
genes identi¢ed in these studies are involved in apoptosis and
ubiquitin/proteasome function and are inhibitors of cell cycle
progression.
FUTURE DIRECTIONS
The development of autoimmune disease undoubtedly involves
the complex interplay of many genes. Although the number and
type of genes are not yet known, global assessment of gene ex-
pression is a very powerful approach for gaining insight into
these processes. Gene identi¢cation will certainly contribute to
advancing our understanding of the molecular basis for autoim-
mune disease and to our identi¢cation of novel therapeutic tar-
gets. Within a relatively short period of time, the information
learned from the application of microarray technology to address
complicated biological questions has not only met but often ex-
ceeded expectations. Despite their success, however, microarray
studies are not without their challenges. Continued re¢nement
of these techniques, including development of improved statisti-
cal methods for extracting information from large datasets and
software tools for data processing, management, and storage, will
likely increase the applicability and general use of these technol-
ogies. Additionally, establishing common standards for the pub-
lishing and sharing of microarray-generated data will be
important. The applicability of this technology to the study of
autoimmunity is only beginning to be appreciated. It is likely
that microarray technologies will have a substantial impact on
our understanding of autoimmune disease.
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